Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Turns To Meda In Sweden For Open Door Into Consumer Market

This article was originally published in The Tan Sheet

Executive Summary

The deal is subject to 90% of Meda shareholders tendering shares, and the two largest shareholders, accounting for about 30% of shares, already committed to the deal. Mylan will pay around $8.5bn in cash and debt and about $1.4bn in stock.

Advertisement

Related Content

Cold-Eeze Deal Puts Homeopathic Brand At Center Of Mylan Consumer Business
Mylan's Cold-Eeze OTC Acquisition Aims To Leverage Respiratory Expertise
Cold-Eeze Deal Puts Homeopathic Brand At Center Of Mylan Consumer Business
Cold-Eeze Deal Puts Homeopathic Brand At Center Of Mylan Consumer Business
2016 Pharma Dealmaking: Waiting On The High-Value Deals
Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology
Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology
Mylan Confident On Advair Generic First-Round Approval
Meda Pumps Up Iron With Feosol Relaunch, Revamps Neglected OTCs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS108170

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel